XERS — Xeris Biopharma Holdings Inc
NASDAQ · Pharmaceuticals · Pharmaceuticals
- Latest Close
- $6.12
- 30-Day Move
- -12.7%
- Market Cap
- $941M
- Shares Outstanding
- 172,430,000
- P/E Ratio
- 1,633.15
- P/B Ratio
- 97.76
Analyst consensus: Buy · 13 analysts
Xeris Biopharma Holdings Inc
A read-only Alphactor snapshot forXeris Biopharma Holdings Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-27
Topline snapshot
Latest Close
$6.12
30-Day Move
-12.7%
Market Cap
$941M
Shares Outstanding
172,430,000
P/E Ratio
1,633.15
P/B Ratio
97.76
$6.12
-12.7%last 90 delayed daily bars
90D High
$8.42
90D Low
$5.25
Avg Volume
1,913,226
Gross margin is running at 85.4%, which gives a quick read on operating quality before you open the full model.
Net margin is 19.0%, useful for comparing XERS against peers in Pharmaceuticals.
XERS is down 12.7% over the last 30 trading days shown on this page.
Latest operating income is $17M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$7.20
Rule of 40
53.3%
Dark Pool Short %
23.4%
Latest Close
$6.12
30-Day Move
-12.7%
Market Cap
$941M
Shares Outstanding
172,430,000
P/E Ratio
1,633.15
P/B Ratio
97.76
ROE
4.0%
ROA
14.0%
Gross Margin
85.4%
Operating Margin
8.5%
Net Margin
19.0%
Debt / Equity
16.1
Current Ratio
2.19
Latest Revenue
$86M
Revenue
$86M
Gross Profit
$75M
Operating Income
$17M
Net Income
$11M
Gross Margin
8541.0%
Net Margin
19.0%
Current Ratio
2.19
Debt / Equity
16.10
Fair Value
$7.20
Upside / Downside
+17.6%
Signal
Fairly Valued
Implied Growth
18.4%
DCF
$6.79
EV/Rev
$7.61
Growth Assumption
38.3%
Discount Rate
10.5%
Terminal Growth
2.0%
Base FCF
$28M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Moderate growth priced in
Altman Z
0.46
Distress
Piotroski
8
Strong (7-9)
Cash Conversion
51.67x
Rule of 40
53.3%
Strong
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $110M | $-82M | $-95M | $-103M |
| 2023-12-31 | $164M | $-44M | $-62M | $-49M |
| 2024-12-31 | $203M | $-34M | $-55M | $-38M |
| 2025-12-31 | $292M | $25M | $554,000 | $28M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Vanguard Group
Filed 2026-01-29
$88M
+13.8%
D.E. Shaw
Filed 2026-02-17
$59M
+29.7%
Geode Capital Management
Filed 2025-11-12
$34M
+13.4%
Qube Research & Technologies
Filed 2026-02-17
$27M
+6.8%
BlackRock
Filed 2024-08-13
$23M
--
4.23
Consensus
Buy—
—
—
13
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.
Balance Sheet Deep Dive
Balance sheet changes lead income statements by 2-6 quarters. Net debt, receivables days, and goodwill are the lines that move stocks first.